ROCHE HOLDING ADR Aktie

 

Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end of July following nearly a decade of distinguished service at Roche Antonio Vergara......

Vorschau - Nestlé, Novartis und Roche legen im Wochenverlauf die Halbjahreszahlen vor....

Thomas Schinecker kämpft als einziger Pharmaboss um eine Lösung im Preisstreit. Wegen des US-Präsidenten sollen die Preise für neue Therapien in der Schweiz steigen....

Vorschau - Nestlé, Novartis und Roche legen in den kommenden Tagen die Halbjahreszahlen vor....

DOW JONES--Entgegen der schwachen Tendenz an den europäischen Börsen hat der schweizerische Aktienmarkt am Freitag den Handel mit Aufschlägen beendet. Vor allem die Kursgewinne bei den defensiven Index-Schwergewichten Novartis, Roche und Nestle, die ......

Die Zürcher Kantonalbank (ZKB) bringt als erste Anbieterin einen Indexfonds auf den neuen SMI Equal Weight Index der SIX auf den Markt. Das Anlageprodukt soll Schweizer Aktieninvestments breiter diversifizieren und die Dominanz der drei Schwergewichte Nestlé, Novartis und Roche deutlich reduzieren....

Pharma - Roche Diagnostics will sich neu erfinden - mit KI, Daten und völlig neuen Testverfahren....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

WORCESTER, Mass., July 15, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc., (NYSE: THG), a leading property and casualty insurance company, announced today that John "Jack" C. Roche, president and chief executive officer, has informed the company's Board of Directors he plans to......

EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B) will release its third quarter fiscal 2026 earnings on Friday, July 31, 2026. In conjunction with this release, Pat Roche, CEO, and Jennifer Walter, CFO, will host a conference call beginning at 10:00 a.m. ET, which will be simultaneously broadcast live online. Listeners can access the conference call live or in replay mode at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the company's website, and the call replay will remain archived for 45 days. About Moog Inc. Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com Conta...

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Find insight on Roche, Novartis , Ryman Healthcare and more in the latest Market Talks covering health care....

The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to The post FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN appeared first on Pharmaceutical Business review....

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced that the FDA has granted Priority Review to the company's supplemental Biologics License Application for Gazyva/Gazyvaro for the treatment o......

Pharmazie - Die US-Arzneimittelbehörde FDA hat Roche einen beschleunigten Prüfstatus für das Nierenmedikament Gazyva/Gazyvaro erteilt....

Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN.1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the US FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic syndrome in May 2026....

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it introduced the cobas HDV test for use on the cobas 5800/6800/8800 systems, a diagnostic tool for the detection and qu......

Pharma - Roche bringt einen neuen diagnostischen Test für das Hepatitis-D-Virus auf den Markt....

Basel, 14 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus (HDV) RNA, in countries accepting the CE mark. Available on the industry-leading cobas 5800/6800/8800 systems, Roche aims to help healthcare providers in identifying patients and monitoring their care more effectively alongside newly available treatments....